for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ImmunoGen, Inc.

IMGN.OQ

Latest Trade

5.13USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.80

 - 

7.07

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Immunogen Announces Initial Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin In Recurrent Ovarian Cancer

May 13 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES INITIAL DATA FROM FORWARD II STUDY EVALUATING MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH AVASTIN® IN RECURRENT OVARIAN CANCER, REGARDLESS OF PLATINUM STATUS.IMMUNOGEN - COMBINATION DEMONSTRATES PROMISING ANTI-TUMOR ACTIVITY WITH CONFIRMED OVERALL RESPONSE RATE OF >60% IN PATIENTS WITH HIGH FRΑ EXPRESSIO.

Immunogen Reports Recent Progress And First Quarter 2020 Financial Results

May 1 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.17.Q1 EARNINGS PER SHARE ESTIMATE $-0.15 -- REFINITIV IBES DATA.SEES FY 2020 REVENUE $60 MILLION TO $65 MILLION.Q1 REVENUE $13.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.9 MILLION.FINANCIAL GUIDANCE FOR 2020 REMAINS UNCHANGED.FY2020 EARNINGS PER SHARE VIEW $-0.68, REVENUE VIEW $62.7 MILLION -- REFINITIV IBES DATA.

Immunogen Reports Q4 Earnings Per Share $0.03

Feb 14 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND 2019 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.03.Q4 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA.FOR 2020, EXPECTS REVENUES BETWEEN $60 MILLION AND $65 MILLION.FOR 2020, EXPECTS OPERATING EXPENSES BETWEEN $165 MILLION AND $170 MILLION.FOR 2020, EXPECTS CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2020 TO BE BETWEEN $170 MILLION AND $175 MILLION.IMMUNOGEN - EXPECTS THAT ITS CURRENT CASH, PROCEEDS FROM RECENT OFFERING, CASH RECEIPTS FROM PARTNERS, WILL FUND OPERATIONS INTO SECOND HALF OF 2022.

Immunogen Announces Pricing Of Public Offering Of 21.3 Mln Common Shares Priced At $4.25per Share

Jan 23 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 21.3 MILLION COMMON SHARES PRICED AT $4.25PER SHARE.

Immunogen Announces Proposed Public Offering Of Common Stock

Jan 22 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.IMMUNOGEN INC - INTENDS TO USE PROCEEDS OF OFFERING, TOGETHER WITH ITS EXISTING CAPITAL, TO FUND ITS OPERATIONS, AMONG OTHER THINGS.

Immunogen Expects To Report $176 Mln Of Cash And Cash Equivalents

Jan 13 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN INC - EXPECT TO REPORT THAT CO HAD ABOUT $176 MILLION OF CASH AND CASH EQUIVALENTS AS OF DEC 31, 2019.

ImmunoGen Reports Third-Quarter 2019 Financial Results

Nov 1 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.15.Q3 REVENUE $13.3 MILLION VERSUS $10.9 MILLION.SEES FY 2019 REVENUE $65 MILLION TO $70 MILLION.Q3 REVENUE ESTIMATE $9.9 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.18 -- REFINITIV IBES DATA.SEES 2019 OPERATING EXPENSES BETWEEN $170 MILLION AND $175 MILLION.SEES CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2019, BETWEEN $170 MILLION AND $175 MILLION..

Immunogen Inc Says Will Not Incur A Loss On Estimated Sub-Lease Arrangement Disclosed On June 27

Aug 5 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN INC -$2.5 MILLION CHARGE WILL BE INCLUDED IN RESULTS FOR PERIOD ENDED JUNE 30 IN CONNECTION WITH DISPOSITION OF SPACE AND EQUIPMENT.IMMUNOGEN INC - WILL NOT INCUR A LOSS ON ESTIMATED SUB-LEASE ARRANGEMENT DISCLOSED ON JUNE 27.

Immunogen Reports Q2 Loss Per Share $0.29

Aug 2 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN REPORTS RECENT PROGRESS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 REVENUE $15.5 MILLION VERSUS $9.3 MILLION.Q2 REVENUE ESTIMATE $9.5 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.UPDATED 2019 FINANCIAL GUIDANCE PROVIDED.SEES FY 2019 REVENUES BETWEEN $40 MILLION AND $45 MILLION.REGISTRATION STUDY FOR MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER ON TRACK TO START BY YEAR-END.FY2019 REVENUE VIEW $36.1 MILLION -- REFINITIV IBES DATA.

Immunogen Says Savings Generated By Restructuring Are Expected To Reduce Co's Quarterly Expenses By More Than 50%

June 27 (Reuters) - ImmunoGen Inc <IMGN.O>::IMMUNOGEN ANNOUNCES COMPLETION OF OPERATIONAL REVIEW.IMMUNOGEN INC SAYS WILL END CURRENT QUARTER WITH ABOUT $240 MILLION ON ITS BALANCE SHEET.IMMUNOGEN INC SAYS WILL PRIORITIZE CONTINUED DEVELOPMENT OF MIRVETUXIMAB SORAVTANSINE AND A SELECT PORTFOLIO OF EARLIER-STAGE CANDIDATES.IMMUNOGEN INC SAYS MONETIZE ITS REMAINING PORTFOLIO AND PLATFORM TECHNOLOGIES THROUGH OUT-LICENSING TRANSACTIONS OR ASSET SALES.IMMUNOGEN INC SAYS REDUCE WORKFORCE BY ABOUT 220 EMPLOYEES, WITH MAJORITY OF EMPLOYEES SEPARATING FROM BUSINESS BY MID-JULY 2019.IMMUNOGEN INC SAYS SAVINGS GENERATED BY RESTRUCTURING ARE EXPECTED TO REDUCE IMMUNOGEN'S QUARTERLY EXPENSES BY MORE THAN 50%.IMMUNOGEN INC SAYS AS RESULT OF WORKFORCE REDUCTION, EXPECTS TO RECORD A ONE-TIME CHARGE TOTALING ABOUT $16.4 MILLION.IMMUNOGEN INC SAYS CHARGE EXPECTED TO BE RECORDED IN QUARTER ENDING JUNE 30, AND RELATED CASH PAYMENTS WILL BE SUBSTANTIALLY PAID OUT BY JUNE 30, 2020.IMMUNOGEN INC SAYS CASH RUNWAY EXTENDED THROUGH READOUT OF MIRVETUXIMAB SORAVTANSINE PIVOTAL TRIAL IN OVARIAN CANCER.IMMUNOGEN - OPERATIONAL REVIEW COMMENCED FOLLOWING ANNOUNCEMENT THAT FORWARD I, CO'S PHASE 3 CLINICAL TRIAL EVALUATING MIRVETUXIMAB DID NOT MEET PRIMARY ENDPOINT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up